ANTABIO has developed a portfolio of first-in-class programs targeting high unmet needs in the antibacterial space. In 2013 ANTABIO received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases up to preclinical candidate nomination. In 2015 ANTABIO received a second Wellcome Trust Seeding Drug Discovery Award (€4.0 Million) to support the development of novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients, and this lead subsequently in 2017 to a CARB-X award (potentially up to $8.9 Million) to continue development up to clinical trials.
MBLi: Metallo Beta-Lactamases inhibitors
Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual > €30 billion additional costs to public health and > 100,000 deaths due to drug-resistant bacterial infections. In the horizon 2050, alarming reports claim that antimicrobial resistance will be the first cause of death in the world, killing more than 10 million people each year. Current antibacterial chemotherapy is becoming increasingly inadequate due to the rise of resistance, mainly related to the spread of genes encoding various carbapenemases, including the metallo ß-lactamase (MBL) enzymes like NDM type, for which no inhibitors are currently available or under clinical development.
ANTABIO is developing a novel, safe and potent inhibitor of bacterial MBLs. It will be administered with a carbapenem to treat hospitalized patients suffering from complicated Gram-negative infections.ANTABIO’s lead compounds potentiate the efficacy of the carbapenem antibiotic meropenem against Carbapenem Resistant Enterobacteriacae (CRE) NDM-1 strains in animal infection models, and restore carbapenem sensitivity in broad range of MBL-containing clinical isolates in laboratory susceptibility studies. Evaluation of preclinical candidate compounds is in progress.
PEi : Pseudomonas Elastase inhibitors (powered by CARB-X)
Cystic fibrosis (CF) is a life-threatening disease, caused by mutation in the CFTR chloride channel, affecting ~70,000 sufferers worldwide. The majority (>80%) of adult CF patients have acute and chronic Pseudomonas aeruginosa lung infections, due to impaired ciliary clearance, causing progressive and irreversible lung damage resulting in early death. Adaptive mechanisms such as biofilm formation allow Pseudomonas to resist immune pressures and all antibiotic therapies, leading to therapeutic failure, recurrent exacerbations and respiratory failure.
ANTABIO’s PEi program, powered by CARB-X, seeks to develop an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting the three corner-stones of Pseudomonas pathogenesis: virulence, stealthiness and persistence. ANTABIO has developed a safe and tractable lead series with potent whole cell activity against the Pseudomonas LasB elastase secreted by clinical CF isolates and excellent potential for inhaled administration.
Antibiotic-resistant infections require prolonged and/or more costly treatment, extended hospital stays, additional doctor visits and healthcare use, resulting in greater morbidity and mortality compared with infections that are susceptible to antibiotics. ESKAPE Pathogens including Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii are often associated with mechanisms of resistance classified as urgent threats by CDC. Antabio is seeking new discovery and development opportunities to strengthen its portfolio of first-in-class programs targeting high unmet needs in the antibacterial space. By partnering with Antabio, you will access our expert international expertise and dedicated antimicrobial drug discovery team to your program. Antabio has a flexible approach to different partnering and collaborative frameworks, e.g. co-developments, in-licensing deals, acquisition of IP… Please contact us.